Patents by Inventor Frank Hulstaert

Frank Hulstaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV COMBINATION THERAPY
    Publication number: 20070048281
    Abstract: The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon.
    Type: Application
    Filed: May 3, 2006
    Publication date: March 1, 2007
    Applicant: INNOGENETICS N.V.
    Inventors: Geert Maertens, Erik Depla, Christina Stichele, Frank Hulstaert
  • HCV combination therapy
    Publication number: 20050037018
    Abstract: The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon.
    Type: Application
    Filed: June 21, 2004
    Publication date: February 17, 2005
    Applicant: INNOGENTICS N.V.
    Inventors: Geert Maertens, Erik Depla, Christina Stichele, Frank Hulstaert
  • Differential diagnosis of neurological diseases
    Patent number: 6670137
    Abstract: The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: December 30, 2003
    Assignee: Innogenetics N.V.
    Inventors: Eugeen VanMechelen, Hugo Vanderstichele, Frank Hulstaert
  • HLA-B27 assay
    Patent number: 6613535
    Abstract: This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: September 2, 2003
    Assignee: Becton, Dickinson andCompany
    Inventors: Joachim Albrecht, Frank Hulstaert, Rosette Becker
  • Differential diagnosis of neurological diseases
    Publication number: 20020019016
    Abstract: The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.
    Type: Application
    Filed: June 27, 2001
    Publication date: February 14, 2002
    Inventors: Eugeen Vanmechelen, Hugo Vanderstichele, Frank Hulstaert